The Importance of Adrenomedullin (AM) on ACTH-Cortisol-Glucose Axis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hyperglycemia is frequent manifestations of the human metabolic response to systemic inflammatory response syndrome (SIRS),sepsis and septic shock, and are implicated in the clinical outcome.
Adrenomedullin is elevated in SIRS, sepsis and septic shock and has been demonstrated the inhibitory role on insulin and adrenocorticotropic hormone secretion.
Our hypothesis is that: AM elevation after SIRS could be the responsible to maintain hyperglycemia
| Condition | Intervention | Phase |
|---|---|---|
|
Systemic Inflammatory Response Syndrome Hyperglycemia |
Procedure: Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin |
Phase 2 |
| Study Type: | Observational |
| Study Design: | Observational Model: Defined Population Primary Purpose: Screening Time Perspective: Cross-Sectional Time Perspective: Prospective |
| Official Title: | The Importance of Adrenomedullin (AM) on Pituitary-Adrenal Axis and Glucose Kinetics in Pediatric Patients With Systemic Inflammatory Response Syndrome |
| Estimated Enrollment: | 20 |
| Study Start Date: | January 2006 |
| Study Completion Date: | October 2006 |
Studies in cultured vascular endothelial cells and vascular smooth muscle cells demonstrate that cytokines strongly stimulate adrenomedullin production and release.
Adrenomedullin has been measured in a wide range of clinical researches. Of all conditions investigated, the greatest increment in plasma adrenomedullin has been observed in septic shock. It appears that AM is directly responsible for the hypotension characteristic of septic shock. Studies have shown that administration of AM and AMBP-1 before the onset of sepsis (i.e., pretreatment) prevents transition from the hyperdynamic phase to the hypodynamic phase in the progression of sepsis, attenuates tissue and organ damage, and reduces sepsis-induced mortality.
Two groups described the effects of AM on the pituitary. Taken together, these studies suggest that AM has a role in inhibiting ACTH release.
Mulder et al. first reported the stimulatory effects of adrenomedullin on insulin secretion from isolated rat islets. In direct contrast to this, Martínez et al. clearly demonstrated the inhibitory role of adrenomedullin on insulin secretion in vitro.
Eligibility| Ages Eligible for Study: | 2 Years to 16 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Children above 2 years, submitted to elective cardiopulmonary bypass (CPB, only interatrial or ventricular communication) with no endocrine disease or infection.
Exclusion Criteria:
- Children with endocrine disease, undernutrition, with some medication that might interfere in the study (corticosteroids.
Contacts and Locations| Brazil | |
| Childrens Institute | |
| Sao Paulo, SP, Brazil, 05403000 | |
| Study Director: | Thelma Okay, PHD | Childrens Institute / Molecular Biology |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00459511 History of Changes |
| Other Study ID Numbers: | FMUSP/ cappesq 675/05 |
| Study First Received: | April 11, 2007 |
| Last Updated: | April 11, 2007 |
| Health Authority: | Brazil: National Committee of Ethics in Research |
Keywords provided by University of Sao Paulo:
|
Adrenomedullin Glucose Insulin Systemic Inflammatory response Syndrome |
Pediatric Cortisol ACTH |
Additional relevant MeSH terms:
|
Hyperglycemia Systemic Inflammatory Response Syndrome Glucose Metabolism Disorders Metabolic Diseases Inflammation Pathologic Processes Shock Adrenocorticotropic Hormone Insulin Cortisol succinate Hydrocortisone acetate Hydrocortisone 17-butyrate 21-propionate Hydrocortisone Hydrocortisone-17-butyrate Adrenomedullin |
Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Hypoglycemic Agents Anti-Inflammatory Agents Therapeutic Uses Dermatologic Agents Bronchodilator Agents Autonomic Agents Peripheral Nervous System Agents Anti-Asthmatic Agents Respiratory System Agents Cardiotonic Agents Cardiovascular Agents |
ClinicalTrials.gov processed this record on June 18, 2013